Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trabectedin - Johnson & Johnson/University of Illinois

Drug Profile

Trabectedin - Johnson & Johnson/University of Illinois

Alternative Names: Ecteinascidin; Ecteinascidin-743; ET-743; NSC-684766; Yondelis

Latest Information Update: 17 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Illinois
  • Developer European Organisation for Research and Treatment of Cancer; Fred Hutchinson Cancer Research Center; Johnson & Johnson; Mario Negri Institute for Pharmacological Research; National Cancer Institute (USA); PharmaMar; Taiho Pharmaceutical
  • Class Antineoplastics; Dioxoles; Small molecules; Tetrahydroisoquinolines
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors; Macrophage inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer; Soft tissue sarcoma
  • Phase III Fallopian tube cancer; Peritoneal cancer
  • Phase II Leiomyosarcoma; Liposarcoma; Meningioma; Mesothelioma; Solid tumours
  • No development reported Breast cancer; Prostate cancer

Most Recent Events

  • 14 Oct 2019 Trabectedin market licensed to Specialised Therapeutics Asia in Australia, New Zealand and South-East Asia
  • 14 Oct 2019 Specialised Therapeutics Asia announces intention to submit regulatory filling to the Therapeutic Goods Administration (TGA) in Australia
  • 13 Oct 2019 Specialised Therapeutics Asia announces intention to launch trabectedin in Australia via Special Access Program on November 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top